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↑ What is "already known" in this topic: {#box1}
========================================

Phenylketonuria is one of the most prevalent metabolic genetic disorders. Mutations in phenylalanine hydroxylase gene cause this disease. More than 800 different mutations are registered on the *PAH* mutation database.

→ What this article adds: {#box2}
=========================

Mutation analysis of *PAH* gene study (exons 6, 7, 8, 11 and 12) in Iranian patients with PKU was screened. These mutations showed regional variations useful in genetic counselling and prenatal testing in different ethnic groups. We found three novel intronic variants and two previously unreported mutations. Our data proved the heterogenic status of *PAH* gene mutations.

Introduction {#s1}
============

Phenylketonuria (PKU, OMIM 261600), a common metabolic genetic disorder, is identified by the lack of phenylalanine hydroxylase (PAH) enzyme (EC 1.14.16.1) activity ([@R1]). Phenylalanine (Phe) conversion to tyrosine by this enzyme is the main pathway for Phe metabolism, and this activity is dependent on tetrahydrobiopterin (BH4) presence as a cofactor ([@R2]). If this disease cannot be diagnosed in the first days after birth, it will contribute to the accumulation of phenylalanine in the patient's body fluids with side effects such as failure in growth and brain damages ([@R3]). Newborn screening programs for PKU diagnosis are important postnatal requirement tests in many countries. The Guthrie test is the most applicable method for this purpose and has been used for more than 40 years ([@R4]).Based on blood Phe concentrations, PKU can be classified to classic PKU, mild PKU and mild hyperphenylalaninemia (HPA) ([@R5]).

The human *PAH* gene (GenBank: AF404777) with 13 exons is located on chromosome 12q22-q24.1, spanning about 90 kb, which encodes a polypeptide with 452 amino acids ([@R6]). The broad spectrum of mutations in *PAH* gene is the main etiology of this disease, and more than 800 different mutations are registered on the *PAH* mutation database; most of them are missense.

These mutations can make the enzyme structure and activity dysregulated which leads to variable phenotypes based on their severity to be observed ([@R7]). The presence of different disease-causing mutations in the biallelic *PAH* gene contributes to the compound heterozygosity status in most patients ([@R8]). The regional prevalence of PKU varies worldwide, and the highest frequency of this disease is observed among Caucasians with a rate of 1/10,000 per live births ([@R5]).

Iran is a country with a high number of consanguine marriages showing a rate of 1.6 in 3,627 ([@R9]). Surveying *PAH* gene mutations is applicable in genetic counseling for prenatal diagnosis and presentation of an efficient dietary program for PKU patients ([@R10]). This study identifies the genetic mutation status of a group of Iranian PKU patients to expand the mutation database of different ethnic groups within this population proving beneficial for mutation panel designs of laboratories and prevention of the birth of children affected with PKU.

Methods {#s2}
=======

Subjects {#s2-0-1}
--------

A total of 30 unrelated PKU patients were chosen from the Institute of Endocrinology and Metabolism of Ali Asghar Hospital between August 2015 and July 2016.

They were accepted into this study after their parents filled out the official consent form provided by the Ethical Committee of Iran University of Medical Sciences. The classification of patients into classic and mild PKU was based on their blood phenylalanine concentrations. Most of them were identified during neonatal screening programs by a Guthrie test. These patients, between 8 months to 18 years old, were from different ethnic groups in Iran.

### DNA Extraction: {#s2-0-2}

A 5 ml blood sample was collected from each patient. The genomic DNA was extracted from leukocytes isolated from EDTA anticoagulated blood, using a DNA purification Genet Bio kit (South Korea). DNA Purity and quality were assessed by NanoDrop Spectrophotometer (Thermo Scientific™, USA) and 1% agarose gel respectively.

### PCR: {#s2-0-3}

The choice of *PAH* gene exons including 6, 7, 8, 11, and 12 was based on their high mutation rates in previous literature ([@R6], [@R11]). These 5 exons and their adjacent intronic regions were separately amplified by PCR on the T100™ Thermal Cycler system (Bio-Rad Laboratories, Hercules, CA, USA) ([Fig. 1](#F1){ref-type="fig"}).
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The primers were chosen from previous studies ([Table 1](#T1){ref-type="table"}) ([@R12]). PCR reactions were carried out in a total volume of 25 μl containing 2.4 µL of 2× reaction buffer, 2 µL of genomic DNA templates, 0.1 µL of Taq DNA polymerase (5 U/µL), 0.7 µL of each primer, 1.5 µL MgCl~2~ (50 mM) and 0.5 µM of dNTP (10 mM). The cycling program of PCR was 94 ˚C denaturation for 3 min, followed by 35 cycles of denaturation at 94 ºC for 45 s, annealing at 59 ˚C for 30 s, extension at 72 ºC for 45 s, and a final extension step at 72 ºC for 3 min. The 1% agarose gel was used for electrophoresis of PCR amplicons.

###### The list of primer sequences and expected PCR product sizes

  ------- -------------------------- ---------------------------- --------------------
  Exons   Primers                    Annealing temperature (°C)   PCR product length

  6       F: TGCCCTGCTTGAGACACCTA\   60                           283
          R: TCCTCCCCCAACTTTCTGC                                  

  7       F: CCTCTGACTCAGTGGTGA\     59                           256
          R: CTTGCAGCAGGAAAAG                                     

  8       F: CTGAGTCTGGCTTGGCTTAA\   58                           194
          R: CTCATTTGAGAAATTCAGGT                                 

  11      F: TGCAGCAGGGAATACTGA\     60                           260
          R: AGATGAGTGGCACCAGT                                    

  12      F: TCCAAATGGTGCCCT\        57                           232
          R: GGCGATGGTAGGGAA                                      
  ------- -------------------------- ---------------------------- --------------------

### DNA Sequencing: {#s2-0-4}

The PCR products were purified and sequenced using PCR forward and reverse primers by the Applied Biosystems 3730 DNA Analyzer (Macrogen, Seoul, Korea) using the classic Sanger's method.

Data Analysis {#s2-0-5}
-------------

Mutations and polymorphisms were detected by software and programs including ChromasPro (Technelysium, South Brisbane Australia), Sequence Scanner (Applied Biosystems, US), Mutation Surveyor (SoftGenetics, Pennsylvania, USA), and nucleotide blast program of NCBI. These ones were then identified by comparison with the reference sequence in GenBank (www.ncbi.nlm.nih. gov/genbank), available genetic data in *PAH* database (<http://www.PAHdb.mcgill.ca>), and SNP database of NCBI ([www.ncbi.nlm.nih.gov/snp](www.ncbi.nlm.nih.gov/snp)).

The clinical significance of mutations was characterized by using ClinVar ([www.ncbi.nlm.nih.gov/clinvar/](www.ncbi.nlm.nih.gov/clinvar/)) database. The analysis of new variants was carried out by Mutation Taster (<http://www.mutationtaster.org/>) and CADD (<http://cadd.gs.washington.edu/>) online bioinformatics tools.

Results {#s3}
=======

The patients (15 females and 15 males), aged between 8 months to 18 years old, were examined. They were from different parts of Iran, and their ethnicity was also diverse such as Kurdish, Azeri, and Persian. The rate of consanguine marriage was 53%, and most of the parents were third cousins. A total of 8 different mutations consisting of 5 missense mutations, 1 splice mutation, 1 nonsense mutation, and 1 Silent/Splice mutation were characterized in 14 alleles. The rate of mutation detection was about 23.3%. Three polymorphisms and four intronic novel variations were characterized as well.

The mutations, including c.782G\>A, c.838 G\>A, c.842C\>T, c.721C\>T, c.727C\>T, c.1197A\>T, c.781C\>T and IVS11+1G\>C, the polymorphisms including c.696A\>G, c.735G\>A and c.1155G\>C and the novel intronic variants including IVS6+44T\>G, IVS6+36T\>G, and IVS10-15A\>C were identified ([Table 2](#T2){ref-type="table"}). The survey of pathogenic variations in ClinVar database also proved their pathogenic effect ([Table 3](#T3){ref-type="table"}). The genotype and phenotype information of patients were demonstrated in [Table 4](#T4){ref-type="table"}. Some associations were also observed in this study and one of them, including R243X mutation and V245V polymorphism was shown in [Fig. 2](#F2){ref-type="fig"}. The mean quality value of surrounding nucleotides of these variants was higher than 50 which proved their accuracy. The PHRED score of these novel variants showed their non-pathogenic effect ([Table 5](#T5){ref-type="table"}).
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###### Relative frequency of variations and prediction of their effec

  ----------- ------------------ ------------------ --------- --------------------- -------- ----------- -----------------
  Location    Systematic name\   Trivial name\      No. of\   Relative frequency\   phyloP   phastCons   Prediction
              (DNA level)        (protein effect)   alleles   (%)                                        

  Exon7       c.782G\>A          p .R261Q           4         6.66                  6.198    1           Disease causing

  Exon7       c.781C\>T          p .R261X           2         3.33                  2.582    1           Disease causing

  Exon7       c.838G\>A          p .E280K           1         1.66                  6.203    1           Disease causing

  Exon7       c.842C\>T          p .P281L           2         3.33                  6.203    1           Disease causing

  Exon7       c.721C\>T          p .R241C           1         1.66                  4.439    1           Disease causing

  Exon7       c.727C\>T          p .R243X           2         3.33                  2.751    1           Disease causing

  Exon 11     c.1197A\>T         p .V399V           1         1.66                  0.423    1           Disease causing

  Intron11    c.1199+1G\>C       IVS11+1G\>C        1         1.66                  6.012    1           Disease causing

  Exon 6      c.696A\>G          p .Q232Q           7         11.6                  -3.252   0.005       polymorphism

  Exon7       c.735G\>A          p .V245V           7         11.6                  0.873    1           Polymorphism

  Exon11      c.1155G\>C         p .L385L           2         3.3                   -0.213   0.749       Polymorphism

  Intron6     c.706+36T\>G       IVS6+36 T\>G       1         1.6                   -0.172   0           Polymorphism

  Intron 6    c.706+44T\>G       IVS6+44T\>G        1         1.6                   -0.986   0.004       Polymorphism

  Intron 10   c.1066-15A\>C      IVS10-15A\>C       3         5                     0.479    0           Polymorphism
  ----------- ------------------ ------------------ --------- --------------------- -------- ----------- -----------------

###### Clinical significance of mutations

  ------------- ------------- -----------------------
  Mutation      rs Number     Clinical significance
  R261Q         rs62508698    Pathogenic
  R261X         rs5030850     Pathogenic
  E280K         rs62508698    Pathogenic
  P281L         rs5030851     Pathogenic
  R241C         rs76687508    Pathogenic
  R243X         rs5030846     Pathogenic
  V399V         rs199475584   Pathogenic
  IVS11+1G\>C   rs62509015    Likely pathogenic
  ------------- ------------- -----------------------

###### Genotypes and characteristics of 12 patients

  ----------- ----------- --------------- ---------------- ---------- ----------- ----------------------------------
  Patients\   Location    Genotypes       Classification   HPA Type   Ethnicity   Pre-treatment Phe levels (mg/dl)
  ID                                                                              

  5           Exon 11     L385L/U         Heterozygote     Classic    Azeri       21.5

  6           Exon 7      V245V/U\        Heterozygote     Mild HPA   Persian     18.4
                          E280K/U                                                 

  7           Exon 7      R261Q/ U        Heterozygote     Mild HPA   \           \
                                                                      Persian     16.7

  7           Exon 6      Q232Q/ U        Heterozygote                            

  8           Exon 7      V245V/U         Heterozygote     Mild HPA   Kurdish     14

  9           Exon 6      Q232Q/ Q232Q    Homozygote       Mild HPA   Persian     15

  11          Exon 7      P281L/ P281L    Homozygote       Classic    Persian     25

  12          Exon 7      R241C/U\        Heterozygote     Classic    Azeri       21.1
                          V245V/U                                                 

  14          Exon 7      R261Q/U         Heterozygote     Classic    Persian     24

  15          Exon 6      Q232Q/ Q232Q    Homozygote       Classic    Persian     26

                          R261X/R261X     Homozygote                              

  16          Exon 6      Q232Q/ Q232Q    Homozygote       Classic    Azeri       25

  18          Exon 11     V399V/U         Heterozygote     Classic    Persian     28.8

              Exon 7      V245V           Homozygote                              

  19          Exon 7      R243X/ R243X\   Homozygote       Classic    Azeri       22.9
                          V245V/ V245V                                            

  22          Exon 11\    L385L/U\        Heterozygote     Classic    Persian     23.4
              Intron 11   IVS11+1G\>C/U                                           

  25          Exon 7      R261Q           Homozygote       Classic    Azeri       25.5
  ----------- ----------- --------------- ---------------- ---------- ----------- ----------------------------------

###### The PHRED score of new variants

  -------------- -------------
  Variant        PHRED Score
  IVS6+36 T\>G   2.980
  IVS6+44T\>G    2.380
  IVS10-15A\>C   2.560
  -------------- -------------

Discussion {#s4}
==========

Phenylketonuria, a metabolic autosomal recessive genetic disorder, is the consequence of *PAH* gene deficiency. The hallmark of this disease is high blood serum Phe levels with a low-Phe diet as the cornerstone of its treatment ([@R13]). Mutations in the BH4 gene also resulted in hyperphenylalaninemia, and identification of related mutations to *PAH* enzyme can be applicable in the prescription of BH4 based therapies ([@R14]). Patients were diagnosed based on their high blood Phe and in order to confirm mild HPA cases for having *PAH* mutations, analysis of DHPR and biopterin-neopterin was carried out.

In this study, molecular characterization of exons 6, 7, 8, 11, and 12 in 30 Iranian patients showed a 23.3% mutation detection rate. Ten percent of patients were homozygote for mutations. Three polymorphisms including Q232Q (11.6%) in exon 6, V245V (11.6%) in exon 7 (11.6%) and L385L (3.33%) in exon 11 were also identified. The R261Q mutation (6.66%) in exon 7 was observed in two patients in heterozygote form and one patient in homozygote form which affects a CpG mutation hot spot in nucleotide 782 of *PAH* gene. The explanation of this mutation mechanism is by the 5-methylcytosine deamination at a CpG dinucleotide site which contributes to the change of amino acid Arg to Glutamine. This one is the second most common mutation in Turkey, which is also common in European nations like France (17%), and Italy (16%) ([@R15], [@R16]). The presence of Mediterranean mutations in our patients may prove the historical connection between Iranian and Mediterranean populations.

The R261X mutation which is the result of C to T conversion at codon 781 of *PAH* gene is placed in its catalytic domain (residues 118-427) ([@R17]). P281L (3.33%), a missense mutation in homozygote form, is the result of C to T substitution at codon 842 of *PAH* gene. This nucleotide position is in the region of cofactor binding domain. P281L has been identified in classic PKU patients frequently. Previous studies in Iran have also reported this mutation ([@R11]).

R243X (3.3%) as a nonsense mutation is located in exon 7 of *PAH* gene, which was observed along with V245V as a polymorphism in one classic patient. These ones were in homozygote form and had located in 21^th^ and 29^th^ base of exon 7 respectively. Two associations in heterozygote patients, including R241C (1.66%) with V245V and E280K (1.66%) with V245V were also reported, which have not been reported previously in *PAH*db. R241C is classified as the BH4-responsiveness mutation reported for the first time in the Iranian population.

The splice mutation IVS11+1G\>C/U (1.66%) and L385L polymorphism were observed in intron 11 and exon 11 of one classic PKU patient. The V399V (1.66%) mutation had been identified in the Chinese population for the first time ([@R17]). The c.1197 nucleotide is located at the 3\'-end of exon 11 at position -3′ of the exon-intron boundary, and transition of A to T in this position cause exon skipping as a post-transcriptional event which can result in deficient *PAH* mRNA ([@R18]). This heterozygote one was observed in a classic patient and was the first report of this mutation in Iran.

Conclusion {#s5}
==========

The results of our study proved the existence of heterogeneous mutations in different ethnic groups in Iran. The highest rate of mutations was observed in exon 7, and no mutation was observed in exon 8. It should be considered that our results showed two mutations which had not been reported previously in Iran.

So by monitoring diverse ethnic groups in Iran, other novel mutations will be easier to find and identify. This data can be useful for genetic counseling and carrier detection tests and as a base to start further research from.
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